Transfusion of blood products should improve tissue oxygenation and reduce negative consequences of anaemia. At the same time, adverse effects of transfusion, such as infections, immunologic reactions and mistransfusion, could be deleterious. Most transfusion guidelines suggest looking at the combination of haemoglobin or haematocrit levels in addition to clinical signs in the decision making process for a blood transfusion. The problem with such indications is that the clinical evaluation may be misleading in severely ill patients and haemoglobin levels that impair oxygen delivery cannot be determined easily. Many studies attempted to establish more convenient parameters, such as oxygen saturation from mixed and central venous blood, tissue oxygen extraction and other methods. Although the results from these studies are conflicting, it appears that global oxygenation parameters are a good indicator for a blood transfusion in some categories of critically ill patients.
INTRODUCTION
According to the World Health Organisation, anaemia represents a condition of decreased haemoglobin (Hgb) concentration (<12 g/dL in women and <13 g/dL in men). In a critically ill population, two-thirds of patients match this criteria. The aetiology of anaemia in critical illness relates to haemodilution, bleeding, blood sampling, increased haemolysis, nutritional deficiencies, blunted erythropoietin production, abnormalities in iron metabolism, etc. (1,
2) The ability to develop compensatory mechanisms that would assure metabolic needs, will determine the tolerance of anaemia in each patient. These mechanisms include: blood flow redistribution, increased cardiac output (CO) and increased oxygen extraction ratio (ERO2), among others. (3, 4) Negative effects of anaemia are a result of impaired tissue oxygen delivery (DO2) that may increase the risk of morbidity and mortality in critically ill patients, especially at Hgb levels below 5-6 g/dL. (5) The transfusion of blood products should improve tissue oxygenation and reduce negative consequences of anaemia. At the same time, the adverse effects of transfusion, such as infections, immunologic reactions and mistransfusion, could be deleterious. (4) According to the American Society of Anesthesiologists (ASA), the Society of Thoracic Surgeons (STS) and the Society of Cardiovascular Anesthesiologists (SCA), red blood cells (RBCs) should be administered when DO2 decreases below a critical level or when euvolemic patients develop complications from disturbed tissue oxygenation. (1, 6) 
HAEMOGLOBIN/HAEMATOCRIT THRESHOLDS FOR BLOOD TRANSFU-SIONS IN CRITICAL ILLNESS
Although the main goal of RBCs transfusions is to improve oxygen delivery and tissue utilisation, a number of intensivists still use Hgb and haematocrit (Htc) levels as an exclusive transfusion trigger. Since a critical Hgb level that impairs DO2 cannot be easily determined, such clinical practice is questionable. (7 -9) The patient's age, primary diagnosis and clinical symptoms, volume status, aetiology and duration of anaemia, surgery duration, ongoing bleeding, compensatory mechanisms, pulmonary, cardiovascular and cerebrovascular comorbidities, and signs of poor end organ perfusion or ischaemia, should significantly affect decisions for transfusion therapy. (1, 3, 6, 7, 9) Throughout the years, Hgb/ Htc thresholds for RBCs transfusions have decreased considerably, without adverse effects and worsening clinical outcomes. (10, 11) The results of the TRICC study demonstrated that 30 day mortality, frequency of myocardial infarction, acute respiratory distress syndrome (ARDS) and pulmonary oedema were reduced when RBCs were administered at lower Hgb levels or when they were not administered at all. (11) Some other studies of critically ill patients (ABC, CRIT), linked transfusion therapy and the number of transfused units to a higher risk of mortality and prolonged intensive care unit (ICU) and hospital stays. In contrast, similar mortality rates between transfused and nontransfused patients were found in 1,040 septic patients who received a blood transfusion in the observational European SOAP study. In the transfusion group a higher 30-day survival rate was noticed. (12) In the FOCUS study of Carson et al. on high risk elderly patients with underlying cardiovascular disease subjected to the hip surgery, a liberal RBCs transfusion strategy (Hgb≥100 g/L), in comparison to restrictive strategy (Hgb≤80 g/L or symptomatic anaemia), did not affect mortality or reduce inability to walk independently on a 60-day followup, nor did it affect in-hospital morbidity. The study results did not support the hypotheses that a blood transfusion induces long-term immunosuppression that is severe enough to increase the mortality rate by more than 20-25%. ( In septic patients, RBCs transfusions must be assessed individually since optimal transfusion triggers in sepsis are not known and there is no clear evidence that transfusion increases tissue oxygenation. In patients at risk for acute lung injury or ARDS, the administration of RBCs should be avoided. RBCs should not be used as a method of weaning patients from mechanical ventilation. In the absence of acute bleeding, transfusions should be given as single units. (9) The transfusion guidelines from the Croatian Medical Association and the Croatian Society for Quality Improvement in Health Care suggest Hgb 7.0 g/dL as a level at which transfusion therapy must be started in critically ill patients. (15) The guidelines of the European Society of Anaesthesiology suggest a Hgb concentration of 7.0 -9.0 g/dL during active perioperative bleeding. (16) ASA guidelines suggest a Hgb concentration from 6 to 10 g/dL, depending on a patient's clinical status. Transfusions for patients undergoing cardiopulmonary bypass is indicated at a Hgb concentration of 6.0 g/dL. For patients older than 65 and for patients with chronic cardiovascular or respiratory diseases, transfusions are justified at a Hgb concentration of 7,0 g/dL. For stable patients with a Hgb concentration between 7 and 10 g/dL, the benefit of transfusions is unclear. In patients with active bleeding, transfusions are recommended after a blood loss higher than 1,500 mL or 30% of blood volume. Rapid blood loss without immediate control warrants a blood transfusion. (1) The American STS and SCA guidelines suggest transfusions in cardiac patients at a Hgb concentration of 6 g/dL, as this can be lifesaving. Haemoglobin of 7 g/dL represents a reasonable transfusion threshold in most cardiac postoperative patients. Transfusions for Hgb levels above 10 g/dL is not suggested. (6) Because of insufficient primary compensatory mechanisms, damaged ventricular function and oxygen transport, most guidelines recommend higher Hgb concentrations as a transfusion indication in patients with ACS. Also, most transfusion guidelines suggest the use of a clinical assessment in combination with the Hgb concentration.
The problem with such recommendations is that a clinical evaluation may be misleading in severely ill and unstable patients.
GLOBAL OXYGENATION PARAM-ETERS IN CRITICAL ILLNESS
Considering the fact that blood loss estimation, intravascular volume and clinical symptoms are not always adequate (and that there is little scientific evidence to point to a specific Hgb/Htc level as an optimal transfusion trigger), many studies tried to establish more convenient parameters. Most studies directed their efforts to global oxygenation parameters, such as oxygen saturation from mixed and central venous blood (SVO2, ScVO2), DO2, oxygen consumption (VO2) and ERO2. SVO2 indicates the relation between global VO2 and DO2. Tissue dysoxia, indicated by decreased VO2 depending on DO2, usually becomes evident at SVO2 levels of 40-50%. If ERO2 is disturbed, tissue dysoxia may be evident at higher SVO2 levels. SVO2 depends on Hgb concentrations, CO, VO2 and arterial oxygen saturations (SaO2). It should be a key factor in determining the amount of blood loss a critically ill patient can tolerate. (17) Studies on animal models with acute, normovolemic haemodilution, demonstrated that a Hgb concentration of 4 g/dL represents the level when VO2 starts to decline, which corresponds to SVO2 of 44% and ERO2 of 57%. (18, 19) Most investigators used SVO2 and calculated ERO2 as transfusion indicators. Keeping in mind the risks from pulmonary artery catheterisation, the use of these parameters in everyday clinical practice may be difficult. (20) (21) (22) (23) (24) (25) (26) Considering the fact that most critically ill patients in medical or surgical ICUs do not have a pulmonary artery catheter inserted, or it is inserted for a short period of time, a question can be raised whether ScVO2 and ScVO2 derived ERO2 may be used as relevant transfusion indicators. SVO2 reflects the relation between DO2 and VO2 in the upper and lower parts of the body and the heart. ScVO2 reflects the balance between DO2 and VO2 in the cranial part of the body and the brain. Although in normal conditions and healthy individuals SVO2 is higher than ScVO2 (2-5%), this relation may change in shock of any aetiology, severe sepsis, cardiac decompensation, head injury, etc. In these conditions (due to a blood flow redistribution in the upper parts of the body, decreased splanchnic and renal circulation and increased ERO2) ScVO2 may outmatch SVO2 by up to 20% . (27) (28) (29) (30) (31) The use of individual ScVO2 and ERO2 values as transfusion indicators in these conditions is questionable. In the most common situations in the ICU, when SaO2 is near 100%, ERO2 may be calculated from the SaO2 and SVO2 difference, without a need for VO2 and DO2 measurements. (31, 33, 34) When anaemia results in DO2 reduction, ERO2 of 50% represents an indirect indicator of tissue oxygen deficit and may be used as a transfusion trigger. (24) Studies that compared ScVO2 and SVO2 in various clinical situations have still not provided reliable answers on the question of whether or not both of these parameters can be used for the purpose of triggering transfusion therapy. As a result of blood flow redistribution, regional impairment of tissue oxygenation and microcirculation in critically ill patients, the various outcomes of these studies are often inconclusive. Therapeutic procedures in the ICU (oxygenotherapy, assisted ventilation, administration of fluids, inotropes, anaesthetics, analgetics, sedatives etc.) additionally contribute to a disproportionality between ScVO2 and SVO2. (28, 29, 30) 
GLOBAL OXYGENATION PARAM-ETERS AS INDICATORS FOR BLOOD TRANSFUSION
In a study by Paone et al. on 100 cardiovascular patients, SVO2 of 55% was used as a transfusion trigger. The study results showed that blood transfusions were significantly reduced in comparison to the amount of blood that would be transfused if traditional triggers were used. (20) On 60 high risk, surgical, haemodynamically stable patients, Adamczyk et al. assessed the ScVO2 value for a decision for blood transfusions in comparison to the criteria of the French guidelines for blood transfusions in critically ill patients, which is based on a consensus by the French Society of Intensive Care Medicine (SLRF). The French guidelines suggest administration of RBCs according to Hgb levels and the associated clinical state of the patient (10 g/dL -ACS, 9 g/dL -ischemic heart disease, stable heart failure, 8 g/dL > 75 years, severe sepsis, 7 g/dL -other critically ill patients). In the study, patients were retrospectively divided into two groups based on ScVO2 values (< or >70%) prior to transfusion therapy. Each group was additionally divided in two subgroups, depending on whether SLRF criteria were matched. Although the transfusions significantly increased Hgb levels in all patients, ScVO2 was significantly increased only in patients with pretransfusion levels below 70%. Thirteen patients of 20 that were transfused contrary to SLRF recommendations had an ScVO2 < 70%, and regarding the VO2/DO2 relationship they seemed to benefit from the blood transfusion. 54.5% of the patients that received a blood transfusion according to the SRLF criteria had an ScVO2 ≥ 70%, which implies that the VO2/DO2 relation had been adequate and that the patients were transfused in excess. (21) Considering physiologic and pathophysiologic mechanisms for the oxygen exchange at the cellular and tissue levels, ERO2 could be used as the best indicator for transfusion therapy. (22-26, 44, 45) A reduction in ERO2 following the administration of RBCs should point out that a blood transfusion was justified. Bashir et al. compared cerebral and peripheral oxygen saturation in patients subjected to autologous blood transfusions during abdominal aortic aneurysm repair. In the post-transfusion group of patients with decreased ERO2, a statistically significant increase in cerebral oxygen saturation, Hgb concentration, oxygen partial pressure and SVO2 was noticed. (44) On an animal model, Wilkerson et al. tried to determine whether global ERO2 reflects disturbed myocardial metabolism during acute, normovolemic anaemia. The left ventricular metabolism (arterial-coronary sinus lactate) was compared to ERO2. The authors concluded that ERO2 could be a valid indicator of myocardial metabolism in anaemia and that significant myocardial lactate production starts when global ERO2 exceeds 50%, which may serve as an indication for a blood transfusion. (22) On animals subjected to critical left ascending coronary artery stenosis, Levy et al. demonstrated that cardiac failure occurs at higher Htc levels. In the presence of limited coronary vascular reserve, the whole body ERO2 greater than 50% may serve as a valid indicator of myocardial metabolism in anaemia, and may be a useful guide to transfusion therapy. (23) In the study of Orlov et al. on patients subjected to cardiopulmonary bypass (CPB) procedures, the post-transfusion ERO2 values did not change in patients with normal pre-transfusion ERO2 values. In patients with elevated pre-transfusion ERO2 values, a significant reduction in ERO2 levels was noticed after the transfusion. The authors concluded that incorporating ERO2 into the decision on transfusion therapy could substantially reduce post-cardiac surgery RBCs transfusions. (24) Seghal et al. tried to determine whether transfusion practices would have been different if an ERO2 ≥ 45% had been used as a transfusion trigger on patients subjected to CABG procedures. The authors concluded that the use of ERO2 in transfusion algorithms could reduce allogeneic blood transfusion. (25) In a study by O'Farrell et al. on patients subjected to complex cardiac surgical procedures, a decrease in ERO2 was noticed two hours after the administration of RBCs if the baseline ERO2 was elevated. The study suggests that increased ERO2 may be a better transfusion trigger than decreased Hgb concentrations and that using ERO2 in everyday clinical practice may reduce unnecessary blood transfusions. In the study, 40% of transfusions would have been avoided if elevated ERO2 was used as the transfusion trigger instead of Hgb concentrations. (26) On 58 patients admitted to the general ICU, Mung'ayi et al. tried to determine the relation between RBCs transfusions and ERO2, using ScVO2 instead of SVO2. The study showed that blood transfusion did not significantly change ERO2. Changes in Hgb concentrations did not correlate with ERO2 changes following blood transfusions. In patients with a higher APACHE score, a statistically significant relation in the change of ERO2 following blood transfusion was noticed. A subgroup analysis of the patients with pretransfusion ERO2 higher than 0.30 yielded a mean reduction in ERO2 of 0.055. The study results imply that the majority of patients who were transfused, did not physiologically require RBCs, and did not benefit from the increased oxygen content. The authors' comment on the lack of significant changes in the ERO2 was that about 60% of the patients had a baseline ERO2 below 0. 30 
CONCLUSION
Well indicated transfusion therapy will improve patients' clinical outcomes and even save lives. The uncritical administration of blood products will impair patients' primary conditions, cause serious adverse effects and unnecessary financial expenses. Most transfusion guidelines suggest that a combination of Hgb/Htc levels and clinical signs should be used in the decision making process for blood transfusions. The problem with such indications is that clinical evaluation may be misleading in severely ill patients, and Hgb levels that impair oxygen utilisation cannot be easily determined. SVO2 and ERO2 are good indicators that show whether a blood transfusion is really necessary. Whenever possible, this is what should be used in everyday clinical practice. In some patients categories in the ICU, ScVO2 and ERO2 derived from ScVO2 could be used as transfusion indicators, provided that clinicians are familiar with the specific differences between ScVO2 and SVO2 in normal and critically ill patients.
